Thus, the biology of ALK+ NSCLC displays some basic similarities with that of the other major oncogene-driven lung cancer subtype, namely EGFR+ NSCLC, in which the oncogene variant (e.g. exon 19 indels vs. other alterations [6]) and the presence of TP53 mutations [21] influence benefit from TKI and patient survival, as well [22]. The gene discussed is EGFR; the disease is lung cancer.